HIMR

US20210299085 METHODS FOR THE TREATMENT OF INFLAMMATION ASSOCIATED WITH INFECTION (wipo.int) includes a 115 page rebuttal by Professor Gantier of USPTO Examiner comments. Among other things, the rebuttal provides proof of (1) the expertise of Michael Gantier and (2) the significance of STING pathway inhibition by Idronoxil.

Interestingly, I note that the WIPO search report considers the same application to be Novel and Inventive; and cites distinguishing features that the US Examiner seems to have missed (and which Professor Gantier highlighted in his rebuttal)

I suspect that the US patent Examiner will not win this argument; nor any related to the Oligonucleotide patent application that forms the basis of the HIMR License agreement with Noxopharm.

Our association with Professor Gantier and his team at HIMR looks like the deal of the century.